Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16135484rdf:typepubmed:Citationlld:pubmed
pubmed-article:16135484lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:16135484lifeskim:mentionsumls-concept:C1516477lld:lifeskim
pubmed-article:16135484lifeskim:mentionsumls-concept:C0280100lld:lifeskim
pubmed-article:16135484lifeskim:mentionsumls-concept:C1122962lld:lifeskim
pubmed-article:16135484lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:16135484lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:16135484lifeskim:mentionsumls-concept:C0201734lld:lifeskim
pubmed-article:16135484lifeskim:mentionsumls-concept:C0205269lld:lifeskim
pubmed-article:16135484pubmed:issue25lld:pubmed
pubmed-article:16135484pubmed:dateCreated2005-9-1lld:pubmed
pubmed-article:16135484pubmed:abstractTextEpidermal growth factor receptor is expressed in pediatric malignant solid tumors. We conducted a phase I trial of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in children with refractory solid tumors.lld:pubmed
pubmed-article:16135484pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16135484pubmed:languageenglld:pubmed
pubmed-article:16135484pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16135484pubmed:citationSubsetIMlld:pubmed
pubmed-article:16135484pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16135484pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16135484pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16135484pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16135484pubmed:statusMEDLINElld:pubmed
pubmed-article:16135484pubmed:monthSeplld:pubmed
pubmed-article:16135484pubmed:issn0732-183Xlld:pubmed
pubmed-article:16135484pubmed:authorpubmed-author:DanceyJanet...lld:pubmed
pubmed-article:16135484pubmed:authorpubmed-author:DawNajat CNClld:pubmed
pubmed-article:16135484pubmed:authorpubmed-author:FurmanWayne...lld:pubmed
pubmed-article:16135484pubmed:authorpubmed-author:StewartClinto...lld:pubmed
pubmed-article:16135484pubmed:authorpubmed-author:BernsteinMark...lld:pubmed
pubmed-article:16135484pubmed:authorpubmed-author:ReamanGregory...lld:pubmed
pubmed-article:16135484pubmed:authorpubmed-author:BlaneySusan...lld:pubmed
pubmed-article:16135484pubmed:authorpubmed-author:Children's...lld:pubmed
pubmed-article:16135484pubmed:authorpubmed-author:AdamsonPeter...lld:pubmed
pubmed-article:16135484pubmed:authorpubmed-author:IaconoLisa...lld:pubmed
pubmed-article:16135484pubmed:authorpubmed-author:KrailoMarkMlld:pubmed
pubmed-article:16135484pubmed:authorpubmed-author:CroopJames...lld:pubmed
pubmed-article:16135484pubmed:authorpubmed-author:SpeightsRose...lld:pubmed
pubmed-article:16135484pubmed:issnTypePrintlld:pubmed
pubmed-article:16135484pubmed:day1lld:pubmed
pubmed-article:16135484pubmed:volume23lld:pubmed
pubmed-article:16135484pubmed:ownerNLMlld:pubmed
pubmed-article:16135484pubmed:authorsCompleteYlld:pubmed
pubmed-article:16135484pubmed:pagination6172-80lld:pubmed
pubmed-article:16135484pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:16135484pubmed:meshHeadingpubmed-meshheading:16135484...lld:pubmed
pubmed-article:16135484pubmed:meshHeadingpubmed-meshheading:16135484...lld:pubmed
pubmed-article:16135484pubmed:meshHeadingpubmed-meshheading:16135484...lld:pubmed
pubmed-article:16135484pubmed:meshHeadingpubmed-meshheading:16135484...lld:pubmed
pubmed-article:16135484pubmed:meshHeadingpubmed-meshheading:16135484...lld:pubmed
pubmed-article:16135484pubmed:meshHeadingpubmed-meshheading:16135484...lld:pubmed
pubmed-article:16135484pubmed:meshHeadingpubmed-meshheading:16135484...lld:pubmed
pubmed-article:16135484pubmed:meshHeadingpubmed-meshheading:16135484...lld:pubmed
pubmed-article:16135484pubmed:meshHeadingpubmed-meshheading:16135484...lld:pubmed
pubmed-article:16135484pubmed:meshHeadingpubmed-meshheading:16135484...lld:pubmed
pubmed-article:16135484pubmed:meshHeadingpubmed-meshheading:16135484...lld:pubmed
pubmed-article:16135484pubmed:meshHeadingpubmed-meshheading:16135484...lld:pubmed
pubmed-article:16135484pubmed:meshHeadingpubmed-meshheading:16135484...lld:pubmed
pubmed-article:16135484pubmed:meshHeadingpubmed-meshheading:16135484...lld:pubmed
pubmed-article:16135484pubmed:meshHeadingpubmed-meshheading:16135484...lld:pubmed
pubmed-article:16135484pubmed:year2005lld:pubmed
pubmed-article:16135484pubmed:articleTitlePhase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study.lld:pubmed
pubmed-article:16135484pubmed:affiliationDepartment of Hematology-Oncology, Mail Stop 260, St Jude Children's Research Hospital, 332 N Lauderdale, Memphis, TN 38105-2794, USA. najat.daw@stjude.orglld:pubmed
pubmed-article:16135484pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16135484pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:16135484pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:16135484pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:16135484pubmed:publicationTypeClinical Trial, Phase Illd:pubmed
pubmed-article:16135484pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16135484lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16135484lld:pubmed